Das Bhabani S, Devi Uma, Mohan Rao C, Srivastava Vinod K, Rath Pramod K, Das Bhabani S
Departments of Chest and Tubercular Diseases, Pathology, and Biochemistry, Ispat General Hospital, Rourkela -769 005, Orissa, India.
Br J Nutr. 2003 Sep;90(3):541-50. doi: 10.1079/bjn2003936.
Anaemia is a common complication of pulmonary tuberculosis. The precise mechanism of anaemia in pulmonary tuberculosis is not clearly known, but anaemia of inflammation as well as of Fe deficiency has been implicated. Both are common in developing countries. It is extremely difficult to distinguish anaemia of Fe deficiency from anaemia of inflammation with the haematological indices used routinely. Therefore, Fe preparations are usually prescribed for all anaemic patients irrespective of the aetiology. This approach has been questioned. The present study aimed to assess the effect of Fe supplementation on anaemic patients with pulmonary tuberculosis. Adult male patients 15-60 years of age with pulmonary tuberculosis and a blood haemoglobin concentration 80-110 g/l were included in the study; healthy adult males matched for age and socio-economic status were taken as controls. Blood haemoglobin concentration, total erythrocyte count (TEC), packed cell volume (PCV), mean corpuscular volume (MCV), mean corpuscular haemoglobin and serum Fe, total Fe-binding capacity and ferritin were estimated before treatment and 1, 2 and 6 months after treatment. The patients were divided randomly into three groups and during the initial 2 months of treatment were provided with one of three supplementary regimens consisting of placebo, Fe alone or Fe with other haematinics. Significant improvements in haematological indices and Fe status were noticed in all three groups. Blood haemoglobin concentration, MCV and PCV were significantly higher at 1 month in both Fe-supplemented groups than the placebo group. This difference, however, disappeared at 2 and 6 months with similar values in all three groups. The increase of other haematological indices was similar in all groups. Serum Fe and Fe saturation of transferrin were significantly higher in both Fe-supplemented groups than the placebo group up to 2 months; this effect, however, disappeared at 6 months. There was a consistent increase in TEC and decrease in ferritin values up to 6 months in all groups. Radiological and clinical improvement was similar in all three groups. These observations suggest that Fe supplementation in mild to moderate anaemia associated with pulmonary tuberculosis accelerated the normal resumption of haematopoiesis in the initial phases by increasing Fe saturation of transferrin. However, consistent improvement of haematological status was dependent only on the improvement of the disease process.
贫血是肺结核的常见并发症。肺结核中贫血的确切机制尚不清楚,但炎症性贫血以及缺铁性贫血都与之相关。这两种情况在发展中国家都很常见。使用常规血液学指标极难区分缺铁性贫血和炎症性贫血。因此,通常会给所有贫血患者开铁制剂,而不考虑病因。这种方法受到了质疑。本研究旨在评估补充铁剂对肺结核贫血患者的影响。研究纳入了年龄在15至60岁、患有肺结核且血红蛋白浓度为80 - 110 g/l的成年男性患者;选取年龄和社会经济地位相匹配的健康成年男性作为对照。在治疗前以及治疗后1、2和6个月分别测定血红蛋白浓度、红细胞总数(TEC)、红细胞压积(PCV)、平均红细胞体积(MCV)、平均红细胞血红蛋白以及血清铁、总铁结合力和铁蛋白。患者被随机分为三组,在治疗的最初2个月内,给予三种补充方案之一,分别为安慰剂、单独补铁或铁与其他造血剂联合使用。三组的血液学指标和铁状态均有显著改善。在补铁的两组中,1个月时血红蛋白浓度、MCV和PCV均显著高于安慰剂组。然而,这种差异在2个月和6个月时消失,三组的值相似。所有组其他血液学指标的升高情况相似。在补铁的两组中,直至2个月时血清铁和转铁蛋白铁饱和度均显著高于安慰剂组;然而,这种效果在6个月时消失。所有组直至6个月时TEC持续升高,铁蛋白值持续下降。三组的放射学和临床改善情况相似。这些观察结果表明,补充铁剂对于与肺结核相关的轻至中度贫血,通过增加转铁蛋白的铁饱和度,在初始阶段加速了造血的正常恢复。然而,血液学状态的持续改善仅取决于疾病进程的改善。